CSF2 and ovarian carcinoma: Dose escalation and dose expansion study of GM-CSF encoding adenovirus, ONCOS-102, in combination with anti-programmed death ligand-1 (PDL1) antibody, durvalumab, in adults with peritoneal disease who have failed prior standard chemotherapy and have platinum-resistant or refractory epithelial ovarian cancer or colorectal cancer.